BMS 986147Alternative Names: BMS-986147
Latest Information Update: 19 May 2015
At a glance
- Originator Bristol-Myers Squibb
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Immunological disorders
Most Recent Events
- 01 Oct 2014 Phase-I clinical trials in Immunological disorders (In volunteers) in USA (PO)